Mumia Abu-Jamal v. Kerestes

CourtCourt of Appeals for the Third Circuit
DecidedJuly 19, 2019
Docket18-2296
StatusUnpublished

This text of Mumia Abu-Jamal v. Kerestes (Mumia Abu-Jamal v. Kerestes) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mumia Abu-Jamal v. Kerestes, (3d Cir. 2019).

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ______________

No. 18-2296 ______________

MUMIA ABU-JAMAL

v.

JOHN KERESTES, Former Superintendent State Correctional Institution Mahanoy; THERESA DELBALSO, Superintendent State Correctional Institution Mahanoy; JOSEPH SILVA, DOC Director of Bureau of Health Care Services; PENNSYLVANIA DEPARTMENT OF CORRECTIONS; JOHN WETZEL, Secretary of Pennsylvania Department of Corrections; DR. PAUL NOEL, Director of Clinical Service; DR. JAY COWAN, Correct Care Solutions; CHRISTOPHER OPPMAN, DOC Director of Bureau of Health Care Services; DR. JOHN LISIAK, SCI MAHANOY; DR. SHAISTA KHANUM, SCI MAHANOY; SCOTT SAXON, Physician's Assistant, SCI Mahanoy; JOHN STEINHART, SCI MAHANOY, Chief Health Care Administrator

(District Court No. 3-15-cv-00967)

JOHN WETZEL, Secretary of Pennsylvania Department of Corrections; DR. PAUL NOEL, Director of Clinical Service; BUREAU OF HEALTH CARE SERVICES ASSISTANT MEDICAL DIRECTOR; BUREAU OF HEALTH CARE SERVICES INFECTION CONTROL COORDINATOR; CORRECT CARE SOLUTIONS REPRESENTATIVE ON THE HEPATITIS TREATMENT COMMITTEE; CORRECT CARE SOLUTIONS; JOSEPH SILVA, DOC DIRECTOR OF BUREAU OF HEALTH CARE SERVICES; TREATING PHYSICIAN SCI MAHANOY

(District Court No. 3-16-cv-02000) John Wetzel, Paul Noel, Christopher Oppman, Joseph Silva, John Kerestes, Theresa DelBalso, John Steinhart, Bureau of Healthcare Services Assistant Medical Director, Bureau of Healthcare Services Infection Control Coordinator, Appellants ______________

Appeal from the United States District Court for the Middle District of Pennsylvania (D.C. No. 3-15-cv-00967 & 3-16-cv-02000) District Judge: Hon. Robert D. Mariani ______________

Submitted Under Third Circuit L.A.R. 34.1(a) July 12, 2019 ______________

Before: SHWARTZ, KRAUSE, and FUENTES, Circuit Judges.

(Filed: July 19, 2019)

______________

OPINION ______________

SHWARTZ, Circuit Judge.

John Kerestes, Theresa DelBalso, Joseph Silva, John Wetzel, Dr. Paul Noel,

Christopher Oppman, John Steinhart, the Bureau of Health Care Services Assistant

Medical Director, and the Bureau of Health Care Service Infection Control Coordinator

(collectively, the “Department Defendants”) appeal the District Court’s order (1) denying

their motion to dismiss Plaintiff Mumia Abu-Jamal’s Fourth Amended Complaint

(“FAC”), (2) declining to convert the motion to dismiss to a motion for summary

 This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent. 2 judgment, and (3) declining to consider material beyond the pleadings. We will dismiss

the appeal of the orders declining both to convert the motion and to consider factual

material beyond the pleadings for lack of appellate jurisdiction, but affirm the order

denying the Department Defendants’ motion to dismiss based on qualified immunity.

I

A1

Hepatitis C is a virus that affects liver cells. Individuals infected with Hepatitis C

often develop chronic Hepatitis C, resulting in progressive liver inflammation and

fibrosis (scarring) or cirrhosis (extreme scarring). These conditions affect liver function,

and patients with chronic Hepatitis C suffer from anemia, diabetes, and rashes.

In 2013, new antiviral drugs, Harvoni and Sovaldi, were introduced to treat

Hepatitis C. They have a ninety to ninety-five percent success rate, and the American

Association for the Study of Liver Diseases and Center for Disease Control recommend

that “everyone with chronic [H]epatitis C be treated with those anti-viral drugs

irrespective of disease stage.” JA 3318.

The Pennsylvania Department of Corrections and Defendants Wetzel, Oppman,

Noel, Kerestes, Steinhart, and Cowan adopted a new Hepatitis C treatment protocol in

response to the new antiviral drugs. Under the policy, “only inmates with decompensated

cirrhosis with bleeding are authorized to receive the anti-viral drugs.” JA 3320. The

1 The facts described herein are drawn from the FAC, the operative complaint on appeal. 3 Hepatitis C Committee recommends whether an inmate with Hepatitis C will receive the

antiviral treatment.

Abu-Jamal has been an inmate in Pennsylvania State Correctional Institute

Mahoney for years. In 2012, Abu-Jamal tested positive for the Hepatitis C antibody. He

developed a skin rash and increasing glucose levels, indicative of hyperglycemia. In

March 2015, Abu-Jamal was rushed to the hospital after losing consciousness from

extremely high glucose levels causing diabetic shock. Abu-Jamal’s discharge papers

indicated a “guarded” prognosis and medical issues of “diabetes, new onset,

encephalopathy secondary to hyperglycemia, dehydration, acute kidney injury,

hyponatremia, hypokalemia, asymptomatic gallstones, skin rash, anemia and a history of

[H]epatitis C.” JA 3324-25.

In May 2015, Abu-Jamal was again taken to the hospital. He was denied all

family and counsel visitation during that time. His blood work in the hospital indicated

anemia, but the cause of the anemia and his skin rash was undetermined. Although no

Hepatitis C work-up was performed, a scan revealed “irregularities in the architecture of

plaintiff’s liver, a sign of cirrhosis,” and his discharge report noted that he “might be a

suitable candidate for [H]epatitis C treatment.” JA 3330.

Abu-Jamal initially saw some relief, but his skin condition worsened. He

requested blood work to determine the cause of his condition and submitted a report from

a physician who had visited him and who determined that “the skin condition was an

extrahepatic manifestation of [H]epatitis C.” JA 3332. The blood work revealed a viral

4 load indicating that Abu-Jamal has chronic and active Hepatitis C, with more than a 50%

chance Abu-Jamal has cirrhosis and liver damage.

Abu-Jamal repeatedly asked that he be treated with Harvoni or Sovaldi. The

Hepatitis C Committee determined that Abu-Jamal should not be treated with the

antiviral medications. Abu-Jamal alleges that “[t]he sole basis for refusing to provide the

anti-viral drugs to [Abu-Jamal] is monetary cost[,]” and “[t]here is no medical

justification for” this refusal. JA 3338.

B

In May 2015, Abu-Jamal filed suit in the Middle District of Pennsylvania, alleging

constitutional claims against several defendants. Amended pleadings followed, adding

new causes of action and defendants. Abu-Jamal also filed a motion for a preliminary

injunction, which the District Court granted, directing the Department Defendants to treat

Abu-Jamal with the antiviral drugs. See Abu-Jamal v. Wetzel, No. 3:16-CV-2000, 2017

WL 34700, at *20 (M.D. Pa. Jan. 3, 2017).

Abu-Jamal filed the FAC in August 2017, alleging, among other claims,

deprivation of his Eighth Amendment right to medical care for Hepatitis C (Count I), his

skin condition (Count II), and hyperglycemia (Count III), and violations of his First

Amendment right of association (Count VII). The Department Defendants moved to

dismiss under Federal Rule of Civil Procedure 12(b)(6), or in the alternative for summary

judgment based on the factual record developed at the preliminary injunction hearing.

The District Court granted in part and denied in part the Department Defendants’

motion. See generally Abu-Jamal v. Kerestes, No. 3:15-CV-967, 2018 WL 2166052

5 (M.D. Pa. May 10, 2018).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gillespie v. United States Steel Corp.
379 U.S. 148 (Supreme Court, 1964)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Harlow v. Fitzgerald
457 U.S. 800 (Supreme Court, 1982)
Johnson v. Jones
515 U.S. 304 (Supreme Court, 1995)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mayer v. Belichick
605 F.3d 223 (Third Circuit, 2010)
Kelly v. Borough of Carlisle
622 F.3d 248 (Third Circuit, 2010)
Orsatti v. New Jersey State Police
71 F.3d 480 (Third Circuit, 1995)
Dr. Emory M. Ghana v. J. T. Holland
226 F.3d 175 (Third Circuit, 2000)
Brown v. Croak
312 F.3d 109 (Third Circuit, 2002)
Reichle v. Howards
132 S. Ct. 2088 (Supreme Court, 2012)
Robert Small v. Whittick
728 F.3d 265 (Third Circuit, 2013)
Nicholas George v. William Rehiel
738 F.3d 562 (Third Circuit, 2013)
Francis Dougherty v. Philadelphia School District
772 F.3d 979 (Third Circuit, 2014)
Mullenix v. Luna
577 U.S. 7 (Supreme Court, 2015)
Sandra Connelly v. Lane Construction Corp
809 F.3d 780 (Third Circuit, 2016)
Ronald Gillette v. Diane Prosper
858 F.3d 833 (Third Circuit, 2017)
Ari Weitzner v. Sanofi Pasteur Inc
909 F.3d 604 (Third Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Mumia Abu-Jamal v. Kerestes, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mumia-abu-jamal-v-kerestes-ca3-2019.